Mangalam Drugs and Organics Ltd
Mangalam Drugs and Organics Q2 Results 2026 (FY27) statement: Revenue & Margins
Q2 FY27 results statement: what the company reported on revenue, margins and capex.
- Revenue
- ₹79Cr
- Net profit
- −₹7Cr
- Margin
- −1.4%
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Mangalam Drugs and Organics Ltd Q2 FY27 key numbers
- Revenue
- For the quarter ended September 30, 2026, Mangalam Drugs and Organics Limited reported Revenue from Operations of Rs. 783.92 lakhs (Standalone) and Rs. 793.92 lakhs (Consolidated).
As stated in Mangalam Drugs and Organics Ltd's Q2 FY27 results statement · published 6 Nov 2026. Reported figures, not investment advice.
Based on Mangalam Drugs and Organics Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.
The short version
For the quarter ended September 30, 2026, Mangalam Drugs and Organics Limited reported Revenue from Operations of Rs. 783.92 lakhs (Standalone) and Rs. 793.92 lakhs (Consolidated). EBITDA for the quarter ended Sept 30, 2026: Rs 642.20 Lakhs; decreased by 57.7% YoY (Rs 1,517.27 Lakhs in Sept 2025).
From Mangalam Drugs and Organics Ltd's Q2 FY27 earnings-call transcript · updated 6 Nov 2026.
How did Mangalam Drugs and Organics' revenue grow in the September 2026 quarter?
What happened to Mangalam Drugs and Organics' margins in Q2 FY27?
See what Mangalam Drugs and Organics Ltd said on profitability & margins — free account, 30 seconds.
What capex is Mangalam Drugs and Organics planning?
See what Mangalam Drugs and Organics Ltd said on capital expenditure plans — free account, 30 seconds.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Mangalam Drugs and Organics raising money or cutting debt?
See what Mangalam Drugs and Organics Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is Mangalam Drugs and Organics' order book?
Mangalam Drugs and Organics Ltd — Quarterly revenue & net profit
Mangalam Drugs and Organics Ltd Q2 FY27 results — key figures
| ₹ Cr | Q2 FY27 |
|---|---|
| Revenue | 79 |
| Operating profit (EBITDA) | -1 |
| Operating margin | -1.4% |
| Profit before tax | -9 |
| Net profit (PAT) | -7 |
| EPS (₹) | -4.55 |
Source: Mangalam Drugs and Organics Ltd's results filing to NSE (consolidated), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹79 Cr, net loss ₹7 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
Others in Pharmaceuticals & Biotechnology this season
- Kilitch Drugs (Q2 FY27)
14.3%) . Key results statement takeaways from Kilitch Drugs (India) Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- NGL Fine Chem (Q2 FY27)
Consolidated: ₹15,870.73 lakhs . Key results statement takeaways from NGL Fine Chem Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Astrazeneca Phar (Q2 FY27)
Year-on-year revenue growth for the quarter: Rs 7,291.0 million vs Rs 5,590.9 million, approximately 30.5% increase. Key results statement takeaways from Astraz
- Cohance Lifesciences Ltd (Q2 FY27)
Q2 FY27 revenue: INR 4,766 Mn, down 14.2% YoY (Page 8, 9) . Key investor presentation takeaways from Cohance Lifesciences Ltd's Q2 FY27 investor presentation —
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Mangalam Drugs and Organics Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Mangalam Drugs and Organics Ltd Q2 FY27 results?
For the quarter ended September 30, 2026, Mangalam Drugs and Organics Limited reported Revenue from Operations of Rs. 783.92 lakhs (Standalone) and Rs. 793.92 lakhs (Consolidated). EBITDA for the quarter ended Sept 30, 2026: Rs 642.20 Lakhs; decreased by 57.7% YoY (Rs 1,517.27 Lakhs in Sept 2025).
What is Mangalam Drugs and Organics Ltd share price analysis?
Mangalam Drugs and Organics Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹46 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Mangalam Drugs and Organics Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.